Figure - PMC

Skip to main content

View full-text article in PMC

. Author manuscript; available in PMC: 2018 Nov 1.

Published in final edited form as: Biol Blood Marrow Transplant. 2017 Jul 18;23(11):1861–1869. doi: 10.1016/j.bbmt.2017.07.006

Probabilities of PFS and OS according to rituximab maintenance for patients over the age of 65 (A and B) and for patients not in CR1 (C and D) based on landmark analysis. Only patients who are still at risk for failure at day 180 after transplant were included in the plots. Patients who started maintenance rituximab prior to day 180 are counted as maintenance rituximab, while patients who did not start maintenance rituximab by then are counted as no-maintenance rituximab (n=3 in A & B, n=0 in C & D).

Probabilities of PFS and OS according to rituximab maintenance for patients over the age of 65 (A and B) and for patients not in CR1 (C and D) based on landmark analysis. Only patients who are still at risk for failure at day 180 after transplant were included in the plots. Patients who started maintenance rituximab prior to day 180 are counted as maintenance rituximab, while patients who did not start maintenance rituximab by then are counted as no-maintenance rituximab (n=3 in A & B, n=0 in C & D).